This Article Figures Only Full Text Full Text (PDF) View Related Cardiosource Journal Scan Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Nakazawa, G. Articles by Virmani, R. Search for Related Content PubMed PubMed Citation Articles by Nakazawa, G. Articles by Virmani, R. Related Collections Related Articles

CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY

Incidence and Predictors of Drug-Eluting Stent Fracture in Human Coronary Artery

A Pathologic Analysis

Gaku Nakazawa, MD^_*, Aloke V. Finn, MD, Marc Vorpahl, MD^_*, Elena Ladich, MD^_*, Robert Kutys, MS^_*, Isidora Balazs, BS^_*, Frank D. Kolodgie, PhD^_* and Renu Virmani, MD^_*,_*

^_* CVPath Institute, Inc., Gaithersburg, Maryland
Emory University School of Medicine, Atlanta, Georgia

Manuscript received December 8, 2008; revised manuscript received April 23, 2009, accepted May 5, 2009.

^_* Reprint requests and correspondence: Dr. Renu Virmani, Medical Director, CVPath Institute, Inc., 19 Firstfield Road, Gaithersburg, Maryland 20878 (Email: rvirmani{at}cvpath.org).

Objectives: The aim of this study was to perform pathologic assessment on stent fracture.

Background: Clinically, stent fracture has been reported in 1% to 2% of patients after drug-eluting stent (DES) implantation.

Methods: High-contrast film-based radiographs of 177 consecutive lesions from the CVPath DES autopsy registry were reviewed. Stent fracture was graded as I (single-strut fracture), II (2 struts), III (2 struts with deformation), IV (with transection without gap), and V (with transection causing gap in stent segment). The incidence of adverse pathologic findings (thrombosis and restenosis) was assessed histologically.

Results: Stent fracture was documented in 51 lesions (29%; grade I = 10, II = 14, III = 12, IV = 6, and V = 9). Lesions with stent fracture had longer duration after implantation (172 days [interquartile range (IQR) 31 to 630 days] vs. 44 days [IQR 7 to 270 days], p = 0.004), a higher rate of Cypher (Cordis Corp., Miami Lakes, Florida) stent usage (63% vs. 36%, p = 0.001), longer stent length (30.0 mm [IQR 22.0 to 40.0 mm] vs. 20.0 mm [IQR 14.0 to 27.3 mm], p < 0.0001), and a higher rate of overlapping stents (45% vs. 22%, p = 0.003). Although fracture with grade I to IV did not have significant impact on the occurrence of adverse pathologic findings such as thrombosis and restenosis, 67% of the grade V fracture lesions were associated with adverse pathologic findings at fracture sites. Longer stent length, use of Cypher, and longer duration of implant were identified as independent risk factors of stent fracture by logistic regression analysis.

Conclusions: The incidence of stent fracture was 29% lesions at autopsy, which is much higher than clinically reported. A high rate of adverse pathologic findings was observed in lesions with grade V stent fracture, whereas fracture with grade I to IV did not have a significant impact on the pathological outcome.

Key Words: stent fracture • drug-eluting stent • pathology

Abbreviations and Acronyms   BMS = bare-metal stent(s)   DES = drug-eluting stent(s)   IVUS = intravascular ultrasound   LCx = left circumflex coronary artery   RCA = right coronary artery

Related Articles

Drug-Eluting Stent Fracture: Promise and Performance

Andrew J. Carter
J. Am. Coll. Cardiol. 2009 54: 1932-1934. [Full Text] [PDF]

This article has been cited by other articles:

				M. Del Trigo, P. Jimenez-Quevedo, C. Fernandez-Golfin, E. Vano, R. Delgado-Bolton, F. Alfonso, N. Gonzalo, A. Kallmeyer, L. Montes, N. Escribano, et al. Very Late Mycotic Pseudoaneurysm Associated With Drug-Eluting Stent Fracture Circulation, January 17, 2012; 125(2): 390 - 392. [Full Text] [PDF]

				M. Vorpahl and J. R. Foerst Letter by Vorpahl and Foerst Regarding Article, "Impact of Sirolimus-Eluting Stent Fracture on 4-Year Clinical Outcomes" Circ Cardiovasc Interv, December 1, 2011; 4(6): e54 - e54. [Full Text] [PDF]

				B. Hibbert and E. R. O'Brien Coronary stent fracture Can. Med. Assoc. J., August 9, 2011; 183(11): E756 - E756. [Full Text] [PDF]

				H. Umeda, T. Kawai, N. Misumida, T. Ota, K. Hayashi, M. Iwase, H. Izawa, S. Sugino, T. Shimizu, Y. Takeichi, et al. Impact of Sirolimus-Eluting Stent Fracture on 4-Year Clinical Outcomes Circ Cardiovasc Interv, August 1, 2011; 4(4): 349 - 354. [Abstract] [Full Text] [PDF]

				R. N. Nair and K. Quadros Coronary Stent Fracture: A Review of the Literature Cardiac Cath Lab Director, February 1, 2011; 1(1): 32 - 38. [Abstract] [PDF]

				A. Caixeta, A. J. Lansky, P. W. Serruys, J. B. Hermiller, P. Ruygrok, Y. Onuma, P. Gordon, M. Yaqub, K. Miquel-Hebert, S. Veldhof, et al. Clinical Follow-Up 3 Years After Everolimus- and Paclitaxel-Eluting Stents: A Pooled Analysis From the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) Randomized Trials J. Am. Coll. Cardiol. Intv., December 1, 2010; 3(12): 1220 - 1228. [Abstract] [Full Text] [PDF]

				J. Gomez-Lara, H. M. Garcia-Garcia, Y. Onuma, S. Garg, E. Regar, B. De Bruyne, S. Windecker, D. McClean, L. Thuesen, D. Dudek, et al. A Comparison of the Conformability of Everolimus-Eluting Bioresorbable Vascular Scaffolds to Metal Platform Coronary Stents J. Am. Coll. Cardiol. Intv., November 1, 2010; 3(11): 1190 - 1198. [Abstract] [Full Text] [PDF]

				S. Garg and P. W. Serruys Coronary Stents: Current Status J. Am. Coll. Cardiol., August 31, 2010; 56(10_Suppl_S): S1 - S42. [Abstract] [Full Text] [PDF]

				D. J. Kereiakes, L. A. Cannon, R. L. Feldman, J. J. Popma, R. Magorien, R. Whitbourn, I. M. Dauber, A. C. Rabinowitz, M. W. Ball, B. Bertolet, et al. Clinical and Angiographic Outcomes After Treatment of De Novo Coronary Stenoses With a Novel Platinum Chromium Thin-Strut Stent: Primary Results of the PERSEUS (Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System) Trial J. Am. Coll. Cardiol., July 20, 2010; 56(4): 264 - 271. [Abstract] [Full Text] [PDF]

				S. R. Dixon, C. L. Grines, and W. W. O'Neill The Year in Interventional Cardiology J. Am. Coll. Cardiol., May 18, 2010; 55(20): 2272 - 2286. [Full Text] [PDF]

				A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, G. K. Feld, B. H. Greenberg, J. Hall, M. Hlatky, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, et al. Highlights of the Year in JACC 2009 J. Am. Coll. Cardiol., January 26, 2010; 55(4): 380 - 407. [Full Text] [PDF]

				A. J. Carter Drug-Eluting Stent Fracture: Promise and Performance J. Am. Coll. Cardiol., November 17, 2009; 54(21): 1932 - 1934. [Full Text] [PDF]